Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: A propensity-matched analysis

International Journal of Radiation Oncology Biology Physics

Volumn 91, Issue 1, 2015, Pages 109-115

  Minniti, Giuseppe ^a,b   Scaringi, Claudia ^a   Lanzetta, Gaetano ^b   Terrenato, Irene ^c   Esposito, Vincenzo ^b   Arcella, Antonella ^b   Pace, Andrea ^c   Giangaspero, Felice ^b   Bozzao, Alessandro ^a   Enrici, Riccardo Maurizi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; TOXICITY;

DNA METHYLTRANSFERASES; KARNOFSKY PERFORMANCE STATUS; METHODS AND MATERIALS; NEWLY DIAGNOSED GLIOBLASTOMA; PROGNOSTIC FACTORS; PROGRESSION FREE SURVIVAL; PROMOTER METHYLATION; TREATMENT OUTCOMES;

PATIENT TREATMENT;

CORTICOSTEROID; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG DOSE REDUCTION; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; METHYLATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPENSITY SCORE; RADIATION DOSE; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; AGE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DNA METHYLATION; DRUG ADMINISTRATION; METABOLISM; MORTALITY; PROCEDURES; REGRESSION ANALYSIS; TIME; VERY ELDERLY;

ADRENAL CORTEX HORMONES; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLIOBLASTOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROPENSITY SCORE; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922968559     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2014.09.013     Document Type: Article

References (26)

1. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol 2012;14(Suppl. 5):v1-v49.
2. Villà S, Viñolas N, Verger E, et al. Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys 1998;42:977-980.
3. Mohan DS, Suh JH, Phan JL, et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 1998;42:981-987.
4. Marijnen CA, van den Berg SM, van Duinen SG, et al. Radiotherapy is effective in patients with glioblastoma multiforme with a limited prognosis and in patients above 70 years of age: A retrospective single institution analysis. Radiother Oncol 2005;75:210-216.
5. Keime-Guibert F, Chinot O, Taillandier L, et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007;356:1527-1535.
6. Bauman GS, Gaspar LE, Fisher BJ, et al. A prospective study of short course RT in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994;29:835-839.
7. Hoegler DB, Davey P. A prospective study of short course radiotherapy in elderly patients with malignant glioma. J Neurooncol 1997;33:201-214.
8. McAleese JJ, Stenning SP, Ashley S, et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: Matched pair survival analysis with MRC controls. Radiother Oncol 2003;67:177-182.
9. Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial. J Clin Oncol 2004;22:1593-1598.
10. Gállego Pérez-Larraya J, Ducray F, Chinot O, et al. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: An ANOCEF phase II trial. J Clin Oncol 2011; 29:3050-3055.
11. Malmström A, Grønberg BH, Marosi C, et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916-926.
12. Wick W, Platten M, Meisner C, et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: The NOA-08 randomised, phase 3 trial. Lancet Oncol 2012; 13:707-715.
13. Minniti G, De Sanctis V, Muni R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008;88:97-103.
14. Sijben AE, McIntyre JB, Roldán GB, et al. Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008;89:97-103.
15. Brandes AA, Franceschi E, Tosoni A, et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: Correlation with MGMT promoter methylation status. Cancer 2009;115:3512-3518.
16. Gerstein J, Franz K, Steinbach JP, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010;97:382-386.
17. Minniti G, Lanzetta G, Scaringi C, et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 2012;83:93-99.
18. Minniti G, Scaringi C, Baldoni A, et al. Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. Int J Radiat Oncol Biol Phys 2013;86:285-291.
19. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999;59:793-797.
20. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963-1972.
21. Austin PC. Comparing paired vs non-paired statistical methods of analyses when making inference about absolute risk reduction in propensity score matched samples. Stat Med 2011;30:1292-1301.
22. Hansen B, Bowers J. Covariate balance in simple, stratified and clustered comparative studies. Stat Sci 2008;23:219-236.
23. Iacus SM, King G, Porro G. CEM: Coarsened exact matching software. J Stat Softw 2009;30:1-27.
24. Barker CA, Chang M, Chou JF, et al. Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. J Neurooncol 2012;109:391-397.
25. Behm T, Horowski A, Schneider S, et al. Concomitant and adjuvant temozolomide of newly diagnosed glioblastoma in elderly patients. Clin Neurol Neurosurg 2013;115:2142-2146.
26. Minniti G, Salvati M, Arcella A, et al. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. J Neurooncol 2011;102:311-316.